|1.||Mascagni, Paolo: 7 articles (01/2015 - 01/2005)|
|2.||Dinarello, Charles A: 4 articles (01/2015 - 01/2005)|
|3.||Fossati, Gianluca: 3 articles (01/2015 - 01/2005)|
|4.||Modena, Daniela: 2 articles (01/2015 - 01/2005)|
|5.||Reznikov, Leonid L: 2 articles (01/2015 - 01/2005)|
|6.||Pozzi, Pietro: 2 articles (01/2015 - 01/2005)|
|7.||Shein, Na'ama A: 2 articles (05/2011 - 12/2009)|
|8.||Shohami, Esther: 2 articles (05/2011 - 12/2009)|
|9.||Siegmund, Britta: 2 articles (05/2011 - 01/2005)|
|10.||Lewis, Eli C: 2 articles (05/2011 - 01/2005)|
05/01/2011 - "ITF2357 treatment both ameliorates the severity scores in arthritis models and prevents bone destruction. "
05/01/2011 - "In the present study, the antiinflammatory effect of a potent HDACi, ITF2357, was explored in different experimental models of arthritis. "
05/01/2011 - "Treatment of acute arthritis (Streptococcus pyogenes cell wall [SCW] arthritis) with ITF2357 showed that joint swelling and cell influx into the joint cavity were reduced. "
05/01/2011 - "To examine the effect of HDAC inhibition on joint destruction, ITF2357 was applied to both rat adjuvant arthritis and mouse collagen type II arthritis. "
05/01/2011 - "Inhibition of HDAC activity by ITF2357 ameliorates joint inflammation and prevents cartilage and bone destruction in experimental arthritis."
01/01/2005 - "The histone deacetylase inhibitor ITF2357 reduces production of pro-inflammatory cytokines in vitro and systemic inflammation in vivo."
05/01/2008 - "In dextran sulphate sodium- and trinitrobenzene sulphonic acid-induced colitis, treatment with ITF2357 was superior to suberoylanilide hydroxamic acid as shown by macroscopic and histological amelioration of inflammation, by reduced production of interferon gamma (IFN gamma) and by increased production of IL10. "
|3.||Closed Head Injuries
05/01/2011 - "Using a well-characterized, clinically relevant mouse model of closed head injury, we demonstrated that a single dose of ITF2357 administered 24 h after injury improves neurobehavioral recovery and reduces tissue damage. "
12/01/2009 - "Using a well-characterized, clinically relevant mouse model of closed head injury (CHI), we demonstrate that a single dose of ITF2357 administered 24 h postinjury improves neurobehavioral recovery from d 6 up to 14 d postinjury (improved neurological score vs. vehicle; P< or =0.05), and that this functional benefit is accompanied by decreased neuronal degeneration, reduced lesion volume (22% reduction vs. vehicle; P< or =0.01), and is preceded by increased acetylated histone H3 levels and attenuation of injury-induced decreases in cytoprotective heat-shock protein 70 kDa and phosphorylated Akt. "
|4.||Juvenile Rheumatoid Arthritis (Juvenile Idiopathic Arthritis)
05/01/2011 - "We also review the safety and efficacy of givinostat (ITF 2357) in the treatment of systemic onset juvenile idiopathic arthritis (SOJIA) and its influence on the cytokine networks in SOJIA. "
01/23/2015 - "ITF2357 (generic givinostat) is an orally active, hydroxamic-containing histone deacetylase (HDAC) inhibitor with broad anti-inflammatory properties, which has been used to treat children with systemic juvenile idiopathic arthritis. "
05/01/2011 - "Here we show that oral administration of the HDAC inhibitor ITF2357 to mice normalized streptozotocin (STZ)-induced hyperglycemia at the clinically relevant doses of 1.25-2.5 mg/kg. Serum nitrite levels returned to nondiabetic values, islet function improved and glucose clearance increased from 14% (STZ) to 50% (STZ + ITF2357). "
|1.||HSP70 Heat-Shock Proteins (Heat-Shock Protein 70)
|5.||Histone Deacetylase Inhibitors
|7.||Valproic Acid (Valproate, Semisodium)
|10.||Apoptosis Regulatory Proteins
|2.||Heterologous Transplantation (Xenotransplantation)